
SP 141
CAS No. 1253491-42-7
SP 141( —— )
Catalog No. M22094 CAS No. 1253491-42-7
SP 141 is a MDM2 inhibitor.SP-141 promotes MDM2 auto-ubiquitination and degradation, with anticancer activity.SP141, which bound directly to MDM2, promoting its auto-ubiquitination and degradation by the proteasome.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 77 | In Stock |
![]() ![]() |
10MG | 117 | In Stock |
![]() ![]() |
25MG | 259 | In Stock |
![]() ![]() |
50MG | 433 | In Stock |
![]() ![]() |
100MG | 619 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSP 141
-
NoteResearch use only, not for human use.
-
Brief DescriptionSP 141 is a MDM2 inhibitor.SP-141 promotes MDM2 auto-ubiquitination and degradation, with anticancer activity.SP141, which bound directly to MDM2, promoting its auto-ubiquitination and degradation by the proteasome.
-
DescriptionSP 141 is a MDM2 inhibitor.SP-141 promotes MDM2 auto-ubiquitination and degradation, with anticancer activity.SP141, which bound directly to MDM2, promoting its auto-ubiquitination and degradation by the proteasome.?The compound reduced levels of MDM2 in pancreatic cancer cell lines, as well as their proliferation, with 50% inhibitory concentrations <0.5 μM (0.38-0.50 μM).?Increasing concentrations of SP141 induced increasing levels of apoptosis and G2-M-phase arrest of pancreatic cancer cell lines, whether or not they expressed functional P53.?Injection of nude mice with SP141 (40 mg/kg/d) inhibited growth of xenograft tumors (by 75% compared with control mice), and led to regression of orthotopic tumors.
-
In VitroCell Viability Assay Cell Line:HPAC, Panc-1, AsPC-1, and Mia-Paca-2 pancreatic cancer cell lines. Human primary fibroblasts (IMR90)Concentration:0.01, 0.1, 1, and 10 μM Incubation Time:72 hours Result:IC50s of 0.38, 0.50, 0.36, 0.41, and 13.22 μM for HPAC, Panc-1, AsPC-1, Mia-Paca-2, and IMR90, respectively.Western Blot Analysis Cell Line:HPAC and Panc-1 cells Concentration:0.5 μM Incubation Time:120 minutes Result:Reduced the MDM2 protein levels.Increased the degradation rate of the MDM2 protein in the presence of Cycloheximide (15 μg/mL).
-
In VivoAnimal Model:Nude mice bearing Panc-1 xenograft tumors Dosage:40 mg/kg Administration:Administered by i.p. injection; 5 d/wk for about three weeks Result:Significantly suppressed the growth of pancreatic xenograft tumors. On Day 18, the tumor volume in the treated group was reduced by 75% compared with that in the control group. There were no significant differences in the body weight compared with the control group.
-
Synonyms——
-
PathwayApoptosis
-
TargetMDM2-p53
-
RecptorMdm2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1253491-42-7
-
Formula Weight324.38
-
Molecular FormulaC22H16N2O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (385.35 mM)
-
SMILESCOc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wei Wang, et al. The Pyrido[b]indole MDM2 Inhibitor SP-141 Exerts Potent Therapeutic Effects in Breast Cancer Models. Nat Commun. 2014 Oct 1;5:5086.
molnova catalog



related products
-
RO-5963
RO-5963 is a dual inhibitor of p53-MDM2 and p53-MDMX (IC50s: ~17 nM and ~24 nM, respectively).
-
P53R3
P53R3 is a novel p53 reactivator that restores sequence-specific DNA binding of the endogenously expressed p53(R175H) and p53(R273H) mutants in gel-shift assays.
-
RO-5353
A potent, selective, and orally active p53-MDM2 antagonist with IC50 of 7 nM.